Investigational Drug Information for Rapastinel
✉ Email this page to a colleague
What is the drug development status for Rapastinel?
Rapastinel is an investigational drug.
There have been 15 clinical trials for Rapastinel.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 2nd 2016.
The most common disease conditions in clinical trials are Depressive Disorder, Major, Depressive Disorder, and Depression. The leading clinical trial sponsors are Naurex, Inc, an affiliate of Allergan plc, Allergan, and New York State Psychiatric Institute.
There are nineteen US patents protecting this investigational drug and two hundred and twenty-seven international patents.
Summary for Rapastinel
| US Patents | 19 |
| International Patents | 227 |
| US Patent Applications | 135 |
| WIPO Patent Applications | 74 |
| Japanese Patent Applications | 35 |
| Clinical Trial Progress | Phase 3 (2016-11-02) |
| Vendors | 40 |
Recent Clinical Trials for Rapastinel
| Title | Sponsor | Phase |
|---|---|---|
| Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD) | Naurex, Inc, an affiliate of Allergan plc | Phase 3 |
| Assessment of Effect of Rapastinel on Driving Performance | Naurex, Inc, an affiliate of Allergan plc | Phase 1 |
| Assessment of Abuse Potential of Rapastinel in Humans | Naurex, Inc, an affiliate of Allergan plc | Phase 1 |
Clinical Trial Summary for Rapastinel
Top disease conditions for Rapastinel
Top clinical trial sponsors for Rapastinel
US Patents for Rapastinel
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Rapastinel | ⤷ Sign Up | Spiro-lactam NMDA receptor modulators and uses thereof | Aptinyx Inc. (Evanston, IL) | ⤷ Sign Up |
| Rapastinel | ⤷ Sign Up | Spiro-lactam NMDA modulators and methods of using same | Aptinyx Inc. (Evanston, IL) | ⤷ Sign Up |
| Rapastinel | ⤷ Sign Up | Class of mu-opioid receptor agonists | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (New York, NY) | ⤷ Sign Up |
| Rapastinel | ⤷ Sign Up | Spiro-lactam NMDA receptor modulators and uses thereof | Aptinyx Inc. (Evanston, IL) | ⤷ Sign Up |
| Rapastinel | ⤷ Sign Up | Spiro-lactam NMDA receptor modulators and uses thereof | Aptinyx Inc. (Evanston, IL) | ⤷ Sign Up |
| Rapastinel | ⤷ Sign Up | Spiro-lactam NMDA receptor modulators and uses thereof | Aptinyx Inc. (Evanston, IL) | ⤷ Sign Up |
| Rapastinel | ⤷ Sign Up | Spiro-lactam NMDA receptor modulators and uses thereof | Aptinyx Inc. (Evanston, IL) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Rapastinel
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Rapastinel | Australia | AU2014212484 | 2033-01-29 | ⤷ Sign Up |
| Rapastinel | Brazil | BR112015018087 | 2033-01-29 | ⤷ Sign Up |
| Rapastinel | Canada | CA2898861 | 2033-01-29 | ⤷ Sign Up |
| Rapastinel | Chile | CL2015002121 | 2033-01-29 | ⤷ Sign Up |
| Rapastinel | Chile | CL2015002125 | 2033-01-29 | ⤷ Sign Up |
| Rapastinel | China | CN105229011 | 2033-01-29 | ⤷ Sign Up |
| Rapastinel | Denmark | DK2951183 | 2033-01-29 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
